Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced MTC and Iodine-refractory DTC
NCT02614495Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Feb 2016
- Primary completion
- Sep 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in medullary thyroid carcinoma (MTC), differentiated thyroid carcinoma (DTC), sponsored by Hutchison MediPharma (HMP). Started Feb 2016; status: completed.
02
Drugs
surufatinib
03
Conditions
medullary thyroid carcinoma (MTC)differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT02614495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614495.